The links between innovation, productivity, health and wealth are recognised by many countries and the need to encourage innovation is also apparent. Investing in and encouraging innovation is a priority for many jurisdictions as is the affordability, quality and sustainability of healthcare systems. There is an apparent tension between these goals that can be mitigated with timely policy development work. The Biotechnology Division is looking into how to encourage and foster innovation which addresses health needs and priorities, maximises access to the benefits, and manages the challenges and risks in a way that is beneficial both to innovators and health systems. The following are projects the Division is currently looking into.
Task Force on Biomedicine and Health Innovation
The Task Force on Biomedicine and Health Innovation has been developing a Synthesis Report of the main policy messages that emerge from recent OECD work related to innovation and health. This Synthesis Report will be discussed by the Working Party on Biotechnology in November 2008 and completion of the Synthesis Report expected at the new year.
Biomarkers and Targeted Therapies
Scientific advances in biotechnology are ushering in a new era of medicine: targeted therapies and personalized medicine are coming of age. Traditional medicine manages a disease through standard treatments, without taking account of existing variability between individuals or groups of population. Personalized medicine, in contrast, adapts treatments to the profile of each individual. This revolution in biomedicine is due, in large part, to the discovery of biomarkers.
Emerging Research Models for the delivery of Health Innovation
A new policy report on Emerging Research Models for the Delivery of Health Innovation will be available at the end of 2007. The Report explores the major elements (tools, practices, incentive structures) underpinning new models, or approaches to organising health innovation, in order to improve the efficiency with which laboratory discoveries are translated into new medical treatments.
High-Level Forum on Medicines for Infectious Diseases
The agenda for Action "The Noordwijk Medicines Agenda" was issued at the OECD High-Level Forum on Policy Coherence: Availability of Medicines for Neglected and Emerging Infectious Diseases, held on 20-21 June 2007 in Noordwijk-aan-zee in the Netherlands. Participants included OECD Secretary-General Angel Gurría, high level officials of developed and developing countries and senior representatives from industry, the scientific community, international and non-governmental organisations.
The forthcoming report Pharmacogenetics: Opportunities and Challenges for Health Innovation and Care, examines the challenges facing pharmacogenetics across the health innovation cycle and into the clinic and reviews the impact to date of pharmacogenetics on both pharmaceutical R&D and clinical care.
Uptake and Diffusion of Health-related Biotechnologies
A new report on the Uptake and Diffusion of Health Related Biotechnologies will be available in autumn 2007. The Report identifies the range of incentives and barriers that are affecting the uptake and into the health care sector of health biotechnologies which differ in their stage of development, from innovations that are relatively mature to those that are still very new on the market.
For further information, please contact us at: stibiotech@oecd.org
Source :http://www.oecd.org/document/10/0,3343,en_2649_34537_33790794_1_1_1_37437,00.html
Tidak ada komentar:
Posting Komentar